Fig. 4: The NVT-formulated intranasal peptide vaccine provides protection comparable to BCG against Mtb infection. | npj Vaccines

Fig. 4: The NVT-formulated intranasal peptide vaccine provides protection comparable to BCG against Mtb infection.

From: A vaccine targeting lung resident-memory CD4+ T cell phenotype protects against Mycobacterium tuberculosis in mice

Fig. 4

a Experimental design. C57BL/6 mice (n = 10 per group) were immunized subcutaneously (s.c.) once (at week 0) with BCG, or intranasally (i.n.) twice (at weeks 0 and 3) with NVT, Pep 5′, or NVT-formulated Pep 5′ (Pep 5′ + NVT). Four weeks after the final immunization, mice were infected with HN878 via aerosol exposure. At 4 weeks post-infection, mice were sacrificed for bacterial counts (n = 5 per group) and lung histopathology (n = 5 per group). Bacterial loads in the lungs (b) and spleen (c). H&E staining (d) and inflamed area (e) in lung tissues. The box-and-whisker plots display the median (center line), 25th and 75th percentiles (box), and the minimum and maximum values (whiskers). Statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparisons test. This experiment was performed once. *P < 0.05; ***P < 0.001; ****P < 0.0001; ns not significant.

Back to article page